Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
NCT06708429 · View on ClinicalTrials.gov ↗
Study Summary
Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one of four DNA mismatch repair genes or a terminal deletion of the MSH2-adjacent gene EpCAM. Despite adherence to cancer surveillance programs, many patients still develop colorectal cancer and endometrial cancer. The Prospective Lynch Syndrome Database (PLSD) suggests that more frequent surveillance intervals do not significantly improve cancer risk reduction. The PLSD also revealed that the incidence of colorectal cancer in MLH1 and MSH2 carriers was even higher than previously expected, reaching as high as 41-36% among MLH1 carriers, regardless of ethnic background. The development of colorectal cancer despite surveillance is an unresolved question. Therefore, there is an unmet need for effective cancer prevention strategies.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Study Locations (5)
California
- Beckman Research Institute at City of Hope — Monrovia
Lombardy
- Gastronterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital — Milan
MI
- Dipartimento di Chirurgia Oncologica e Dipartimento di Oncologia Sperimentale Istituto Nazionale Tumori — Milan
PM
- Dipartimento di controllo qualità e rischio chimico biologico, AOOR Villa Sofia Cervello — Palermo
Other
- Chirurgia Generale, Azienda Ospedaliero Universitaria di Cagliari — Cagliari
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2034-06-01 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06708429
The ClinicalTrials.gov registry entry for NCT06708429 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is San Raffaele University, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Lynch Syndrome appearing as the primary indexed condition, and to 1 intervention — of which LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06708429 reports 5 study locations spanning 5 distinct geographic areas — top geographies include California, Lombardy, MI. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06708429 about?
NCT06708429 is a clinical study titled "Lynch Syndrome X-Talk of Enteral Mucosa With Immune System". Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach...
What is the current status of trial NCT06708429?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-06-01. Estimated completion is 2034-06-01.
What conditions does trial NCT06708429 study?
This clinical trial studies the following conditions: Lynch Syndrome, Hereditary Cancer Syndrome, Hereditary Cancer, MLH1 Gene Mutation, HNPCC. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06708429?
The interventions under investigation include: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System) (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06708429?
This trial is sponsored by San Raffaele University, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06708429 being conducted?
This trial has 5 study locations across California, Lombardy, MI, PM. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.